Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The article highlights estimates that the annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000.
As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. Gelrin C is based on the company’s Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue including inflamed cartilage and bone.
The company notes that no off-the-shelf treatment is currently available for the approximately 470,000 annual knee cartilage repair cases in the U.S. Gelrin C is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This cell-free approach avoids the need for cell harvesting, culturing, and re-implantation, which can require multiple surgeries and specialized lab processing.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. The full article is available at https://ibn.fm/yPKU2. For the latest news and updates relating to RGNT, visit the company’s newsroom at https://ibn.fm/RGNT.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements.
